Alexander Grabner1, Christian Faul. 1. aKatz Family Drug Discovery Center and Division of Nephrology and Hypertension, Department of Medicine bDepartment of Cell Biology and Anatomy, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, USA.
Abstract
PURPOSE OF REVIEW: In chronic kidney disease (CKD), multiple factors contribute to the development of cardiac hypertrophy by directly targeting the heart or indirectly by inducing systemic changes such as hypertension, anemia, and inflammation. Furthermore, disturbances in phosphate metabolism have been identified as nonclassical risk factors for cardiovascular mortality in these patients. With declining kidney function, the physiologic regulators of phosphate homeostasis undergo changes in their activity as well as their circulating levels, thus potentially contributing to cardiac hypertrophy once they are out of balance. Recently, two of these phosphate regulators, fibroblast growth factor 23 (FGF23) and Klotho, have been shown to affect cardiac remodeling, thereby unveiling a novel pathomechanism of cardiac hypertrophy in CKD. Here we discuss the potential direct versus indirect effects of FGF23 and the soluble form of Klotho on the heart, and their crosstalk in the regulation of cardiac hypertrophy. RECENT FINDINGS: In models of CKD, FGF23 can directly target cardiac myocytes via FGF receptor 4 and induce cardiac hypertrophy in a blood pressure-independent manner. Soluble Klotho may directly target the heart via an unknown receptor thereby protecting the myocardium from pathologic stress stimuli that are associated with CKD, such as uremic toxins or FGF23. SUMMARY: Elevated serum levels of FGF23 and reduced serum levels of soluble Klotho contribute to uremic cardiomyopathy in a synergistic manner.
PURPOSE OF REVIEW: In chronic kidney disease (CKD), multiple factors contribute to the development of cardiac hypertrophy by directly targeting the heart or indirectly by inducing systemic changes such as hypertension, anemia, and inflammation. Furthermore, disturbances in phosphate metabolism have been identified as nonclassical risk factors for cardiovascular mortality in these patients. With declining kidney function, the physiologic regulators of phosphate homeostasis undergo changes in their activity as well as their circulating levels, thus potentially contributing to cardiac hypertrophy once they are out of balance. Recently, two of these phosphate regulators, fibroblast growth factor 23 (FGF23) and Klotho, have been shown to affect cardiac remodeling, thereby unveiling a novel pathomechanism of cardiac hypertrophy in CKD. Here we discuss the potential direct versus indirect effects of FGF23 and the soluble form of Klotho on the heart, and their crosstalk in the regulation of cardiac hypertrophy. RECENT FINDINGS: In models of CKD, FGF23 can directly target cardiac myocytes via FGF receptor 4 and induce cardiac hypertrophy in a blood pressure-independent manner. Soluble Klotho may directly target the heart via an unknown receptor thereby protecting the myocardium from pathologic stress stimuli that are associated with CKD, such as uremic toxins or FGF23. SUMMARY: Elevated serum levels of FGF23 and reduced serum levels of soluble Klotho contribute to uremic cardiomyopathy in a synergistic manner.
Authors: Maren Leifheit-Nestler; Robert Große Siemer; Kathrin Flasbart; Beatrice Richter; Felix Kirchhoff; Wolfgang H Ziegler; Michael Klintschar; Jan U Becker; Andreas Erbersdobler; Christoph Aufricht; Tomas Seeman; Dagmar-Christiane Fischer; Christian Faul; Dieter Haffner Journal: Nephrol Dial Transplant Date: 2015-12-17 Impact factor: 5.992
Authors: Tamara Isakova; Jessica Houston; Laura Santacruz; Eva Schiavenato; Gabriel Somarriba; William G Harmon; Steven E Lipshultz; Tracie L Miller; Paolo G Rusconi Journal: Pediatr Nephrol Date: 2013-06-06 Impact factor: 3.714
Authors: Ivana Pavik; Philippe Jaeger; Lena Ebner; Carsten A Wagner; Katja Petzold; Daniela Spichtig; Diane Poster; Rudolf P Wüthrich; Stefan Russmann; Andreas L Serra Journal: Nephrol Dial Transplant Date: 2012-11-04 Impact factor: 5.992
Authors: Xiaotian Zhong; Srinath Jagarlapudi; Yan Weng; Mellisa Ly; Jason C Rouse; Kim McClure; Tetsuya Ishino; Yan Zhang; Eric Sousa; Justin Cohen; Boriana Tzvetkova; Kaffa Cote; John J Scarcelli; Keith Johnson; Joe Palandra; James R Apgar; Suma Yaddanapudi; Romer A Gonzalez-Villalobos; Alan C Opsahl; Khetemenee Lam; Qing Yao; Weili Duan; Annette Sievers; Jing Zhou; Darren Ferguson; Aaron D'Antona; Richard Zollner; Hongli L Zhu; Ron Kriz; Laura Lin; Valerie Clerin Journal: J Biol Chem Date: 2020-01-31 Impact factor: 5.157
Authors: Christopher Yanucil; Dominik Kentrup; Isaac Campos; Brian Czaya; Kylie Heitman; David Westbrook; Gunars Osis; Alexander Grabner; Adam R Wende; Julian Vallejo; Michael J Wacker; Jose Alberto Navarro-Garcia; Gema Ruiz-Hurtado; Fuming Zhang; Yuefan Song; Robert J Linhardt; Kenneth White; Michael S Kapiloff; Christian Faul Journal: Kidney Int Date: 2022-05-02 Impact factor: 18.998
Authors: Brian A Bergmark; Jacob A Udell; David A Morrow; Christopher P Cannon; Dylan L Steen; Petr Jarolim; Andrzej Budaj; Christian Hamm; Jianping Guo; KyungAh Im; Julia F Kuder; Eugene Braunwald; Marc S Sabatine; Michelle L O'Donoghue Journal: JAMA Cardiol Date: 2018-06-01 Impact factor: 14.676
Authors: Stefanie Krick; Nathalie Baumlin; Sheyla Paredes Aller; Carolina Aguiar; Alexander Grabner; Juliette Sailland; Eliana Mendes; Andreas Schmid; Lixin Qi; Nicolae V David; Patrick Geraghty; Gwendalyn King; Susan E Birket; Steven M Rowe; Christian Faul; Matthias Salathe Journal: Sci Rep Date: 2017-10-30 Impact factor: 4.379